NCT06963723 Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
| NCT ID | NCT06963723 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alliance Foundation Trials, LLC. |
| Condition | Advanced Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2028-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000 participants in total. It began in 2025-07-01 with a primary completion date of 2028-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to determine whether monthly remote digital financial hardship screening among adults with advanced/metastatic cancer, undergoing outpatient systemic therapy with non-curative intent, improves patient-centered outcomes, including financial worry, health-related quality of life (HRQoL), symptom burden, patient-reported cancer treatment adherence, and exploratory outcomes of overall survival, patient-reported economic burden, patient-reported support received, patient-reported financial coping strategies, and health insurance literacy.
Eligibility Criteria
Inclusion Criteria: 1. Minimum age of 21 2. Understands English and/or Spanish 3. Has a diagnosis of advanced/metastatic cancer 4. Currently undergoing systemic therapy (enteral or parenteral) with non-curative intent 5. Has been receiving treatment for at least 2 months 6. Life expectancy of at least 6 months, in the opinion of the treating oncologist 7. Cognitively able to give informed consent Exclusion Criteria: 1. Under the age of 21 2. Does not understand English or Spanish 3. Has cognitive deficits that would preclude understanding of consent form and/or questionnaires 4. Undergoing treatment with curative intent (e.g., adjuvant chemotherapy for breast, lung, or ovarian cancer, primary curative therapy for testis cancer or lymphoma) 5. Not undergoing systemic therapy (enteral or parenteral) with non-curative intent 6. Receiving treatment for fewer than 2 months 7. Life expectancy is less than 6 months, in the opinion of the treating oncologist
Contact & Investigator
AFT Quality Management Group Inbox
✉ clinicaltrials.queries@alliancefoundationtrials.org📞 617-732-8727
Victoria Blinder, MD, MSc
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT06963723 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Advanced Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06963723 currently recruiting?
Yes, NCT06963723 is actively recruiting participants. Contact the research team at clinicaltrials.queries@alliancefoundationtrials.org for enrollment information.
Where is the NCT06963723 trial being conducted?
This trial is being conducted at Phoenix, United States, Concord, United States, Manchester, United States, New York, United States and 3 additional locations.
Who is sponsoring the NCT06963723 clinical trial?
NCT06963723 is sponsored by Alliance Foundation Trials, LLC.. The principal investigator is Victoria Blinder, MD, MSc at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.